Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Katzav

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Oncogene|July 1, 1993
Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vavS Katzav
Critical Reviews in Oncogenesis|January 1, 1995
Vav: Captain Hook for signal transduction?S Katzav
Molecular and Cellular Biology|August 1, 1995
A functional T-cell receptor signaling pathway is required for p95vav activityJ Wu, S Katzav, A Weiss
International Journal of Cancer|March 15, 1984
Immuno-selection in vivo of H-2D phenotypic variants from a metastatic clone of sarcoma cells results in cell lines of altered metastatic competenceS Katzav, S Segal, M Feldman
Journal of the National Cancer Institute|August 1, 1985
Metastatic capacity of cloned T10 sarcoma cells that differ in H-2 expression: inverse relationship to their immunogenic potencyS Katzav, S Segal, M Feldman
The EMBO Journal|August 1, 1989
vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cellsS Katzav, D Martin-Zanca, M Barbacid
FEBS Letters|February 9, 2000
Vav, a GDP/GTP nucleotide exchange factor, interacts with GDIs, proteins that inhibit GDP/GTP dissociationM Groysman, C S Russek, S Katzav
Journal of the National Cancer Institute|July 1, 1983
Loss of expression of transplantation antigens encoded by the H-2K locus on Lewis lung carcinoma cells and its relevance to the tumor's metastatic propertiesN Isakov, S Katzav, M Feldman, et al.
Oncogene|October 30, 1998
Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformationM Groysman, M Nagano, B Shaanan, et al.
Israel Journal of Medical Sciences|May 1, 1986
General anesthesia during excision of a mouse tumor accelerates postsurgical growth of metastases by suppression of natural killer cell activityS Katzav, J Shapiro, S Segal, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Oncogene|July 1, 1993
Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vavS Katzav
Critical Reviews in Oncogenesis|January 1, 1995
Vav: Captain Hook for signal transduction?S Katzav
Molecular and Cellular Biology|August 1, 1995
A functional T-cell receptor signaling pathway is required for p95vav activityJ Wu, S Katzav, A Weiss
International Journal of Cancer|March 15, 1984
Immuno-selection in vivo of H-2D phenotypic variants from a metastatic clone of sarcoma cells results in cell lines of altered metastatic competenceS Katzav, S Segal, M Feldman
Journal of the National Cancer Institute|August 1, 1985
Metastatic capacity of cloned T10 sarcoma cells that differ in H-2 expression: inverse relationship to their immunogenic potencyS Katzav, S Segal, M Feldman
The EMBO Journal|August 1, 1989
vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cellsS Katzav, D Martin-Zanca, M Barbacid
FEBS Letters|February 9, 2000
Vav, a GDP/GTP nucleotide exchange factor, interacts with GDIs, proteins that inhibit GDP/GTP dissociationM Groysman, C S Russek, S Katzav
Journal of the National Cancer Institute|July 1, 1983
Loss of expression of transplantation antigens encoded by the H-2K locus on Lewis lung carcinoma cells and its relevance to the tumor's metastatic propertiesN Isakov, S Katzav, M Feldman, et al.
Oncogene|October 30, 1998
Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformationM Groysman, M Nagano, B Shaanan, et al.
Israel Journal of Medical Sciences|May 1, 1986
General anesthesia during excision of a mouse tumor accelerates postsurgical growth of metastases by suppression of natural killer cell activityS Katzav, J Shapiro, S Segal, et al.
Pageof 4